Which has better valuation and earnings, IMNM or ABVX?

Immunome has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunome $6.94M 325.72 -$212.39M -$2.38 N/A Abivax N/A N/A -$380.27M -$5.21 N/A

Is IMNM or ABVX more profitable?

Immunome's return on equity of -51.15% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Immunome N/A -51.15% -47.32% Abivax N/A -99.02% -70.26%

Which has higher earnings and valuation, QGEN or IMNM?

Qiagen has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qiagen $2.09B 3.88 $424.88M $1.91 20.61 Immunome $6.94M 325.72 -$212.39M -$2.38 N/A

Is QGEN or IMNM more profitable?

Qiagen has a net margin of 19.16% compared to Immunome's net margin of 0.00%. Qiagen's return on equity of 14.40% beat Immunome's return on equity. Company Net Margins Return on Equity Return on Assets Qiagen 19.16% 14.40% 8.40% Immunome N/A -51.15% -47.32%

Which has stronger valuation and earnings, TGTX or IMNM?

TG Therapeutics has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TG Therapeutics $616.29M 13.87 $447.18M $2.86 19.52 Immunome $6.94M 325.72 -$212.39M -$2.38 N/A

Is TGTX or IMNM more profitable?

TG Therapeutics has a net margin of 65.95% compared to Immunome's net margin of 0.00%. TG Therapeutics' return on equity of 88.73% beat Immunome's return on equity. Company Net Margins Return on Equity Return on Assets TG Therapeutics 65.95% 88.73% 43.44% Immunome N/A -51.15% -47.32%

Which has higher valuation & earnings, IMNM or IBRX?

Immunome has higher earnings, but lower revenue than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunome $6.94M 325.72 -$212.39M -$2.38 N/A ImmunityBio $113.29M 80.52 -$351.40M -$0.85 N/A

Is IMNM or IBRX more profitable?

Immunome has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Immunome's return on equity. Company Net Margins Return on Equity Return on Assets Immunome N/A -51.15% -47.32% ImmunityBio -606.15% N/A -59.53%

Is IMNM or PRAX more profitable?

Praxis Precision Medicines' return on equity of -43.02% beat Immunome's return on equity. Company Net Margins Return on Equity Return on Assets Immunome N/A -51.15% -47.32% Praxis Precision Medicines N/A -43.02% -40.22%

Immunome (IMNM) Competitors

$19.96 +0.56 (+2.89%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$19.87 -0.09 (-0.45%)

As of 06/26/2026 07:57 PM Eastern

Compare

IMNM vs. ABVX, QGEN, TGTX, IBRX, and PRAX

Should you buy Immunome stock or one of its competitors? MarketBeat compares Immunome with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immunome include Abivax (ABVX), Qiagen (QGEN), TG Therapeutics (TGTX), ImmunityBio (IBRX), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry.

How does Immunome compare to Abivax?

Immunome (NASDAQ:IMNM) and Abivax (NASDAQ:ABVX) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

Immunome's return on equity of -51.15% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-51.15%	-47.32%
Abivax	N/A	-99.02%	-70.26%

Immunome has a beta of 2.04, suggesting that its stock price is 104% more volatile than the broader market. Comparatively, Abivax has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market.

In the previous week, Abivax had 2 more articles in the media than Immunome. MarketBeat recorded 3 mentions for Abivax and 1 mentions for Immunome. Immunome's average media sentiment score of 1.89 beat Abivax's score of 0.84 indicating that Immunome is being referred to more favorably in the media.

Company	Overall Sentiment
Immunome	Very Positive
Abivax	Positive

44.6% of Immunome shares are owned by institutional investors. Comparatively, 47.9% of Abivax shares are owned by institutional investors. 7.2% of Immunome shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Immunome presently has a consensus price target of $33.17, suggesting a potential upside of 66.17%. Abivax has a consensus price target of $130.08, suggesting a potential upside of 33.41%. Given Immunome's stronger consensus rating and higher possible upside, equities analysts plainly believe Immunome is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Abivax	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73

Immunome has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	325.72	-$212.39M	-$2.38	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

Summary

Immunome beats Abivax on 11 of the 13 factors compared between the two stocks.

How does Immunome compare to Qiagen?

Qiagen (NYSE:QGEN) and Immunome (NASDAQ:IMNM) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

70.0% of Qiagen shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 9.0% of Qiagen shares are held by company insiders. Comparatively, 7.2% of Immunome shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Qiagen presently has a consensus target price of $43.15, indicating a potential upside of 9.62%. Immunome has a consensus target price of $33.17, indicating a potential upside of 66.17%. Given Immunome's stronger consensus rating and higher possible upside, analysts clearly believe Immunome is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	1 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.38
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Qiagen has a net margin of 19.16% compared to Immunome's net margin of 0.00%. Qiagen's return on equity of 14.40% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
Immunome	N/A	-51.15%	-47.32%

Qiagen has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market. Comparatively, Immunome has a beta of 2.04, indicating that its stock price is 104% more volatile than the broader market.

In the previous week, Qiagen had 4 more articles in the media than Immunome. MarketBeat recorded 5 mentions for Qiagen and 1 mentions for Immunome. Immunome's average media sentiment score of 1.89 beat Qiagen's score of 0.00 indicating that Immunome is being referred to more favorably in the news media.

Company	Overall Sentiment
Qiagen	Neutral
Immunome	Very Positive

Qiagen has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	3.88	$424.88M	$1.91	20.61
Immunome	$6.94M	325.72	-$212.39M	-$2.38	N/A

Summary

Qiagen beats Immunome on 11 of the 17 factors compared between the two stocks.

How does Immunome compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Immunome (NASDAQ:IMNM) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.

TG Therapeutics has a net margin of 65.95% compared to Immunome's net margin of 0.00%. TG Therapeutics' return on equity of 88.73% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	65.95%	88.73%	43.44%
Immunome	N/A	-51.15%	-47.32%

In the previous week, TG Therapeutics and TG Therapeutics both had 1 articles in the media. Immunome's average media sentiment score of 1.89 beat TG Therapeutics' score of 1.87 indicating that Immunome is being referred to more favorably in the news media.

Company	Overall Sentiment
TG Therapeutics	Very Positive
Immunome	Very Positive

58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 8.9% of TG Therapeutics shares are held by insiders. Comparatively, 7.2% of Immunome shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

TG Therapeutics currently has a consensus price target of $58.60, indicating a potential upside of 4.96%. Immunome has a consensus price target of $33.17, indicating a potential upside of 66.17%. Given Immunome's stronger consensus rating and higher probable upside, analysts plainly believe Immunome is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

TG Therapeutics has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market. Comparatively, Immunome has a beta of 2.04, suggesting that its share price is 104% more volatile than the broader market.

TG Therapeutics has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	13.87	$447.18M	$2.86	19.52
Immunome	$6.94M	325.72	-$212.39M	-$2.38	N/A

Summary

TG Therapeutics beats Immunome on 10 of the 16 factors compared between the two stocks.

How does Immunome compare to ImmunityBio?

Immunome (NASDAQ:IMNM) and ImmunityBio (NASDAQ:IBRX) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.

44.6% of Immunome shares are held by institutional investors. Comparatively, 8.6% of ImmunityBio shares are held by institutional investors. 7.2% of Immunome shares are held by insiders. Comparatively, 66.1% of ImmunityBio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Immunome has higher earnings, but lower revenue than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	325.72	-$212.39M	-$2.38	N/A
ImmunityBio	$113.29M	80.52	-$351.40M	-$0.85	N/A

Immunome currently has a consensus target price of $33.17, indicating a potential upside of 66.17%. ImmunityBio has a consensus target price of $14.20, indicating a potential upside of 63.03%. Given Immunome's stronger consensus rating and higher possible upside, research analysts plainly believe Immunome is more favorable than ImmunityBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Immunome has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-51.15%	-47.32%
ImmunityBio	-606.15%	N/A	-59.53%

Immunome has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.03, meaning that its stock price is 97% less volatile than the broader market.

In the previous week, ImmunityBio had 4 more articles in the media than Immunome. MarketBeat recorded 5 mentions for ImmunityBio and 1 mentions for Immunome. Immunome's average media sentiment score of 1.89 beat ImmunityBio's score of -0.03 indicating that Immunome is being referred to more favorably in the media.

Company	Overall Sentiment
Immunome	Very Positive
ImmunityBio	Neutral

Summary

Immunome beats ImmunityBio on 11 of the 16 factors compared between the two stocks.

How does Immunome compare to Praxis Precision Medicines?

Immunome (NASDAQ:IMNM) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

44.6% of Immunome shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 7.2% of Immunome shares are held by company insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Praxis Precision Medicines' return on equity of -43.02% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-51.15%	-47.32%
Praxis Precision Medicines	N/A	-43.02%	-40.22%

In the previous week, Praxis Precision Medicines had 9 more articles in the media than Immunome. MarketBeat recorded 10 mentions for Praxis Precision Medicines and 1 mentions for Immunome. Immunome's average media sentiment score of 1.89 beat Praxis Precision Medicines' score of 0.50 indicating that Immunome is being referred to more favorably in the media.

Company	Overall Sentiment
Immunome	Very Positive
Praxis Precision Medicines	Positive

Immunome has higher earnings, but lower revenue than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	325.72	-$212.39M	-$2.38	N/A
Praxis Precision Medicines	$8.55M	1,068.86	-$303.27M	-$13.37	N/A

Immunome currently has a consensus price target of $33.17, indicating a potential upside of 66.17%. Praxis Precision Medicines has a consensus price target of $566.21, indicating a potential upside of 72.74%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, analysts clearly believe Praxis Precision Medicines is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	4 Strong Buy rating(s)	2.95

Immunome has a beta of 2.04, meaning that its share price is 104% more volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.71, meaning that its share price is 171% more volatile than the broader market.

Summary

Praxis Precision Medicines beats Immunome on 11 of the 16 factors compared between the two stocks.

Get Immunome News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMNM vs. The Competition

Export

Metric	Immunome	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.26B	$3.63B	$7.04B	$12.19B
Dividend Yield	N/A	2.21%	2.66%	6.23%
P/E Ratio	-8.39	21.56	26.13	24.17
Price / Sales	325.72	334.26	556.13	101.82
Price / Cash	N/A	141.14	47.95	55.62
Price / Book	3.47	8.33	10.78	6.36
Net Income	-$212.39M	$23.91M	$3.58B	$337.99M
7 Day Performance	6.51%	3.42%	2.22%	0.10%
1 Month Performance	-11.45%	0.39%	-0.09%	-1.28%
1 Year Performance	127.59%	65.22%	34.39%	27.68%

Immunome Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMNM Immunome	3.5224 of 5 stars	$19.96 +2.9%	$33.17 +66.2%	+127.6%	$2.26B	$6.94M	N/A	40	Positive News High Trading Volume
ABVX Abivax	2.9281 of 5 stars	$98.26 +1.8%	$130.08 +32.4%	+1,217.6%	$7.70B	N/A	N/A	61
QGEN Qiagen	3.2381 of 5 stars	$36.97 -0.3%	$44.98 +21.7%	-21.7%	$7.64B	$2.09B	19.31	5,654	Analyst Upgrade Gap Up
TGTX TG Therapeutics	2.9125 of 5 stars	$50.30 +1.6%	$52.50 +4.4%	+52.0%	$7.58B	$616.29M	17.59	290	Positive News
IBRX ImmunityBio	2.4152 of 5 stars	$7.13 +0.4%	$14.20 +99.2%	+222.6%	$7.44B	$113.29M	N/A	590	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMNM) was last updated on 6/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunome (IMNM) Competitors

IMNM vs. ABVX, QGEN, TGTX, IBRX, and PRAX

How does Immunome compare to Abivax?

Summary

How does Immunome compare to Qiagen?

Summary

How does Immunome compare to TG Therapeutics?

Summary

How does Immunome compare to ImmunityBio?

Summary

How does Immunome compare to Praxis Precision Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNM vs. The Competition

Immunome Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immunome (IMNM) Competitors

IMNM vs. ABVX, QGEN, TGTX, IBRX, and PRAX

How does Immunome compare to Abivax?

Is IMNM or ABVX more profitable?

Which has more risk & volatility, IMNM or ABVX?

Does the media refer more to IMNM or ABVX?

Do institutionals and insiders hold more shares of IMNM or ABVX?

Do analysts recommend IMNM or ABVX?

Which has better valuation and earnings, IMNM or ABVX?

Summary

How does Immunome compare to Qiagen?

Do insiders and institutionals hold more shares of QGEN or IMNM?

Do analysts rate QGEN or IMNM?

Is QGEN or IMNM more profitable?

Which has more risk & volatility, QGEN or IMNM?

Does the media prefer QGEN or IMNM?

Which has higher earnings and valuation, QGEN or IMNM?

Summary

How does Immunome compare to TG Therapeutics?

Is TGTX or IMNM more profitable?

Does the media prefer TGTX or IMNM?

Do insiders & institutionals hold more shares of TGTX or IMNM?

Do analysts rate TGTX or IMNM?

Which has more volatility & risk, TGTX or IMNM?

Which has stronger valuation and earnings, TGTX or IMNM?

Summary

How does Immunome compare to ImmunityBio?

Do institutionals and insiders believe in IMNM or IBRX?

Which has higher valuation & earnings, IMNM or IBRX?

Do analysts rate IMNM or IBRX?

Is IMNM or IBRX more profitable?

Which has more risk and volatility, IMNM or IBRX?

Does the media refer more to IMNM or IBRX?

Summary

How does Immunome compare to Praxis Precision Medicines?

Do institutionals & insiders believe in IMNM or PRAX?

Is IMNM or PRAX more profitable?

Does the media refer more to IMNM or PRAX?

Which has stronger earnings and valuation, IMNM or PRAX?

Do analysts rate IMNM or PRAX?

Which has more volatility and risk, IMNM or PRAX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNM vs. The Competition

Immunome Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools